40+ results for "chief"
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms a
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance system Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c
IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date: October 12 - 14, 2026 Location: Hard Rock Hotel, New York, NY Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a
DP WORLD REAFFIRMS LONG-TERM PARTNERSHIP WITH INDIA AS EXECUTIVE CHAIRMAN H.E. ESSA KAZIM MAKES FIRST VISIT
Executive Chairman H.E. Essa Kazim, Group CEO Mr. Yuvraj Narayan and members of DP World s Global Board of Directors engage with JNPA leadership to explore opportunities for deeper collaboration and future investment. Inauguration of Phase 2 of Nhava Sheva Business Park adds one million square feet of warehousing capacity, backed by an investment of approximately 500 crore ( 52 million), strengthening DP World s integrated logistics ecosystem in India. MUMBAI, India , Oct. 8, 2026 -- DP World has reaffirmed its long-term commitment to India s economic growth and global trade ambitions, as H.E. Essa Kazim, Executive Chairman, made his first visit to the country in his new role, accompanied by Mr. Yuvraj Narayan, Group Chief Executive Officer, and members of DP World s Global Board of Directors.
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows: Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ET Location: NYY Room at the Hard Rock Hotel NYC Mr. Klemp will discuss Mo
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors
WATERTOWN, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Michael Landsittel to its Board of Directors. “We are delighted to welcome Michael to the Remix Board of Directors,” said Pete Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. “His proven track record of
Oak Hill Bio Appoints Joerg Hipp, PhD as Chief Translational Science Officer
CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the appointment of Joerg Hipp, PhD as Chief Translational Science Officer. Dr. Hipp was integral to the development of Oak Hill Bio’s lead asset, rugonersen, and brings extensive expertise in neuroscience, neurodevelopmental disorders, translational science, and biomarkers. “We are thrilled to welcome Joerg to Oak Hill Bio at such an excit
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027 CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic
Cofounder.AI Names Former Google X Leader AJ Thomas Chief Operating Officer
Venture investor, operator and founder coach joins the AI-native startup to scale partnerships and operations, and brings Cofounder.AI to every Good Trouble Ventures portfolio founder LOS ANGELES , Oct. 6, 2026 -- Cofounder.AI, the venture-backed, AI-native startup leveling the playing field for small business owners and entrepreneurs, today announced that AJ Thomas has joined as Chief Operating Officer. Thomas will lead Partnerships and oversee Finance, Legal and HR alongside CEO Clarence Wooten, her former colleague at Google X, Alphabet s Moonshot Factory. At Google X, she served as Global Head of Talent & People Products. She is also cofounder of Troublemaker Ventures, home to the venture fund Good Trouble Ventures and the growth advisory firm The Troublemaker Lab.
SWELECT Appoints Pradeep Kumar Madhur as Chief Business Officer
Former LONGi India business leader to drive growth across EPC, IPP, solar module and channel businesses CHENNAI, India , Oct. 6, 2026 -- SWELECT Energy Systems Limited has appointed Pradeep Kumar Madhur as Chief Business Officer (CBO), effective October 1, 2026. He will lead sales and business development across the company s Engineering, Procurement and Construction (EPC), Independent Power Producer (IPP), channel and solar module businesses. The appointment is aimed at strengthening SWELECT s commercial strategy by bringing its key business verticals under a unified leadership structure. This will enable the company to align its sales and business development efforts across the solar value chain, offering customers an integrated portfolio spanning rooftop and ground-mounted solar projects, long-term solar power solutions and solar modules.
Innospec Schedules Third Quarter 2026 Earnings Release and Conference Call
ENGLEWOOD, Colo., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced that it will release third quarter 2026 earnings results on Tuesday, November 3, 2026 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Wednesday, November 4, 2026, at 9:00 a.m. ET. The public is invited to listen to t
NanoXplore Announces the Creation of an Advisory Board for Its Subsidiary VoltaXplore and Appoints Galvion Founder and Executive Chairman Jonathan Blanshay as Inaugural Member
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- NanoXplore Inc. (“NanoXplore” or the “Company”) (TSX: GRA and OTCQX: NNXPF) today announced that its wholly owned subsidiary, VoltaXplore Inc. (“VoltaXplore”), has created an Advisory Board to provide strategic guidance as it advances its battery manufacturing strategy, and has appointed Mr. Jonathan Blanshay, founder and Chief Executive Officer of Galvion Inc., as its first member. Galvion Inc. is a global defence company that designs, develops and de
Sofwave to Participate in the Jefferies Private MedTech Virtual Summit
SAN CLEMENTE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Private MedTech Virtual Summit on October 7 – 8, 2026. Jefferies Private MedTech Virtual Summit Presentation Format: Corporate overview Presentation Dat
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Sum
Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced it has repurchased 240,124 HYPD common shares at a weighted average price of $3.21* per share and retired its legacy debt of approximately $8.6 million, as it continues its efforts to optimize its capital structure for the benefit of common stockholders. “We have continued to execute on the promises we’ve made to investors,” said Hyunsu Jung, Chief Executive Officer of
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Ribbon cutting ceremony Officially inauguration of Zealand Pharma Research Hub in Cambridge, MA.(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer, EVP, Zealand Pharma; Sumbul Siddiqui, Mayor of Cambridge; Jesper Møller Sørensen, Danish Ambassador to the United States; Adam Steensberg, CEO and President, Zealand Pharma; Martin Nicklasson, Chair of the Board, Zealand Pharma; Utpal Singh, Ch
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. “We are pleased to welcome Noah to Iovance as we pre
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE , Oct. 1, 2026 / PRNewswire / -- Emerald Clinical Trials , a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company s next phase of growth. Michael brings over 30 years of global CRO industry experience. He joins Emerald Clinical after six years with Novotech where he was Chief Operating Officer; prior to that he was CEO at PPC Group for three years and spent 22 years with IQVIA in several regional and global leadership positions. He has helped these organizations through complex transformations, driving significant revenue growth and market leadership, with deep operational experience across Asia-Pacific, including China, Singapore and Australia.
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Serge Rogasik TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness TAPI Steroid manufacturing TAPI Steroid manufacturing TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities, and an extensive global operations n
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational
Decoy Therapeutics to Present at The Small Cap Showcase
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc . (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at The Small Cap Showcase, taking place Thursday, October 1, 2026 in New York City. Mr. Pierce will del
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex
RESTEM to Present at the 2026 Cell & Gene Meeting on the Mesa
MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Chief Medical Officer Keith March, MD, PhD, will present at the 2026 Cell & Gene Meeting on the Mesa, taking place October 5-7, 2026, at the Arizona Biltmore in Phoenix, Arizona. Presentation Details: Date and Time: Monday, October 5, 2026, at 5:30 p.m. MST Format: Corporate presentation
Aro Biotherapeutics Appoints Biotechnology Executive Brett Blackman, Ph.D., to its Board of Directors
PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aro Biotherapeutics, a clinical-stage biotechnology company developing targeted short-interfering RNA (siRNA) medicines for the treatment of diseases with high unmet medical need, today announced the appointment of Brett Blackman, Ph.D., to its Board of Directors. Brett Blackman is Senior Vice President, Chief Operating Officer, and Chief Business Officer at Valo Health, where he leads corporate operations and strategy, business development, allia
Celularity Announces Naveen Jain to Join Board of Directors
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors. Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Chris Hassig, PhD, as Chief Scientific Offi
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. “We are thril
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors. Dr. Ehrnrooth most recently served as Chief Medical Officer of IO Biotech, where she led clinical development strategy for its pipeline of immunomodulatory vaccines for cancer indications with high unmet needs. Mr. Khuong is a seasoned healthcare investor and entrepreneur who curren
Quest PharmaTech Announces Change of Chief Executive Officer
EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be retiring from his position as Quest’s CEO. Dr. Madiyalakan has been the CEO of Quest since August 2006. Mr. Jeff
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
Aleix Prat, MD, PhD Incoming Chief Medical Officer, Ona Therapeutics More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona's $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, transitions to Chief Development
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development - Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of Directors of Lift Therapeutics and assumes role as President - London, September 23, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Daniel Passeri, MSc, JD, as Chief Executive Officer (CEO). Mr. Passeri brings over 30 years of experience in oncology
Engitix appoints Sonia Quaratino, MD, PhD as EVP Chief Medical Officer as its ECM pipeline moves toward clinical development
LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based discovery platforms to transform drug development in oncology, fibrosis and fibro‑inflammatory disease, today announced the appointment of Sonia Quaratino, MD, PhD in the newly created role of Executive Vice President (EVP) Chief Medical Officer (CMO). With more than 35 years of experience spanning immunology and oncology research, clinical development, and strategic leade
Global AI Visionary and Expert Mo Gawdat to Headline Bahrain Fintech Forward 2026
MANAMA, Bahrain , Sept. 23, 2026 -- Former Chief Business Officer of Google X, bestselling author, entrepreneur, and internationally recognised AI expert Mo Gawdat has joined Fintech Forward 2026 s speaker lineup to share his perspective on the future of artificial intelligence, human judgment, and responsible decision-making. Gawdat s participation comes at a time when AI is commanding global attention as businesses, regulators, and the public navigate questions around trust, accountability, and the role of human oversight in increasingly intelligent systems. The region s flagship financial services forum will take place on 7-8 October 2026 at Exhibition World Bahrain, under the theme Finance in the Age of Intelligent Infrastructure .
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company
Ossium Health Hosts U.S. Representative Erin Houchin at Indianapolis Production Facility
Congresswoman tours the operational hub of the world's first organ donor bone marrow bank Inside Ossium's Laboratory (From left) Ossium CEO Kevin Caldwell, Rep. Houchin and Chief Science Officer Erik Woods during a tour of Ossium's laboratory. Rep. Houchin Visits Ossium Health's Indianapolis Facility (From left) Ossium CEO, Co-Founder & President Kevin Caldwell, U.S. Rep. Erin Houchin (R-Ind.) and Chief Science Officer and Co-Founder Erik Woods outside Ossium Health's Indianapolis production fac
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer, and Ajay Nirula, M.D., Ph.D., president and head of research and development, will present an overview of the company at the Oppenheimer Private Life Sciences Company Showcase. The company’s presentation will be on Tuesday, September 29, 20
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate de
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritte